Small molecule · Modulator of Estrogen receptor alpha (ESR1) and Estrogen receptor beta (ESR2) · developed by Lilly
ApprovedFDA, Dec 1997
1Registered trials
What is Raloxifene?
Raloxifene is a selective estrogen receptor modulator (SERM) that binds estrogen receptors and acts as an estrogen agonist in some tissues, such as bone, and as an antagonist in others, such as breast and uterine tissue. It is studied in osteoporosis and in reducing the risk of invasive breast cancer in postmenopausal women.
Summary written with AI from the sources listed at the end of this page.
Invasive breast cancer risk reduction in postmenopausal women with osteoporosis
Invasive breast cancer risk reduction in postmenopausal women at high risk
From the indications section of the FDA label (version of Feb 11, 2026). Read the full label for the exact wording, limitations and safety information.
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.